A carregar...
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Xeljanz(®) (tofacitinib) is an oral small-molecule inhibitor that reversibly inhibits Janus-activated kinase (JAK)-dependent cytokine signaling, thus reducing inflammation. As a result of these mechanisms, effects on the immune system such as a moderate decrease in the total lymphocyte count, a dose...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5743127/ https://ncbi.nlm.nih.gov/pubmed/29317823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S138677 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|